|Description||AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.|
|Synonyms||AS252424; AS 252424; AS-252424.|
Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and...
AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...
PIK-75 was developed as part of a PI 3-kinase drug discovery program. PIK75 attenuates insulin stimulation of Akt/PKB in a range of cell types at 100 nM. The co...
AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for P...
AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
Pilaralisib, also known as XL147, is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, δ, ...
GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.
AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...